Literature DB >> 1359153

Effect of P-glycoprotein expression on sensitivity to hormones in MCF-7 human breast cancer cells.

R Clarke1, S Currier, O Kaplan, E Lovelace, V Boulay, M M Gottesman, R B Dickson.   

Abstract

BACKGROUND: Data obtained from studies of primary human breast cancers and established cell lines indicate that overexpression of the MDR1 gene (also known as PGY1) is associated with decreased expression of steroid hormone receptors and increased expression of epidermal growth factor (EGF) receptors. Other study results indicate that both progestins and triphenylethylene antiestrogens may be substrates for P-glycoprotein, the product of the MDR1 gene. These findings together suggest an association between overexpression of the MDR1 gene and cross-resistance to progestin and antiestrogen therapies.
PURPOSE: This study was designed to determine (a) the ability of MDR1 expression to alter tumor sensitivity to hormone therapy and (b) the role of MDR1 expression in expression of functional hormone receptors in human breast cancer.
METHODS: We transduced MCF-7 cells with MDR1 complementary DNA, using a retroviral vector directing the constitutive expression of the MDR1 gene. Transduced cells (MCF-7MDR1) were examined for ability to produce P-glycoprotein, expression of steroid hormone receptors, and responsivity to antiestrogens. For comparison, we used MCF-7ADR human breast cancer cells, which overexpress MDR1 and have also lost the requirement for 17 beta-estradiol supplementation to form tumors in nude mice. We also investigated the level of EGF-R mRNA expression by using a sensitive RNase protection analysis.
RESULTS: MCF-7MDR1 cells retained both estrogen receptor and progesterone receptor expression as well as sensitivity to 4-hydroxytamoxifen. Expression of the estrogen-inducible pS2 and EGF receptor genes was similar in parental MCF-7 and transduced MCF-7MDR1 cells. EGF receptor expression was increased, and pS2 expression was lost (undetectable) in MCF-7ADR cells.
CONCLUSIONS: The data indicate that overexpression of the MDR1 gene alone confers a multidrug-resistant phenotype, but it does not directly result in either cross-resistance to antiestrogens or a loss of steroid hormone receptor expression. IMPLICATIONS: MCF-7MDR1 cells provide an important model for study of the interactions of cytotoxic drugs, hormones, and the MDR1 glycoprotein in human hormone-responsive breast cancer cells.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1359153     DOI: 10.1093/jnci/84.19.1506

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN: 0027-8874            Impact factor:   13.506


  21 in total

1.  The opposite effects of doxorubicin on bone marrow stem cells versus breast cancer stem cells depend on glucosylceramide synthase.

Authors:  Kaustubh N Bhinge; Vineet Gupta; Salman B Hosain; Seetharama D Satyanarayanajois; Sharon A Meyer; Benny Blaylock; Qian-Jin Zhang; Yong-Yu Liu
Journal:  Int J Biochem Cell Biol       Date:  2012-06-19       Impact factor: 5.085

2.  Regulatory role of human AP-endonuclease (APE1/Ref-1) in YB-1-mediated activation of the multidrug resistance gene MDR1.

Authors:  Ranajoy Chattopadhyay; Soumita Das; Amit K Maiti; Istvan Boldogh; Jingwu Xie; Tapas K Hazra; Kimitoshi Kohno; Sankar Mitra; Kishor K Bhakat
Journal:  Mol Cell Biol       Date:  2008-09-22       Impact factor: 4.272

3.  Modulation of function of three ABC drug transporters, P-glycoprotein (ABCB1), mitoxantrone resistance protein (ABCG2) and multidrug resistance protein 1 (ABCC1) by tetrahydrocurcumin, a major metabolite of curcumin.

Authors:  Pornngarm Limtrakul; Wanida Chearwae; Suneet Shukla; Chada Phisalphong; Suresh V Ambudkar
Journal:  Mol Cell Biochem       Date:  2006-09-08       Impact factor: 3.396

4.  Self-assembled Multifunctional DNA Nanoflowers for the Circumvention of Multidrug Resistance in Targeted Anticancer Drug Delivery.

Authors:  Lei Mei; Guizhi Zhu; Liping Qiu; Cuichen Wu; Huapei Chen; Hao Liang; Sena Cansiz; Yifan Lv; Xiaobing Zhang; Weihong Tan
Journal:  Nano Res       Date:  2015-09-15       Impact factor: 8.897

5.  Prolonged drug selection of breast cancer cells and enrichment of cancer stem cell characteristics.

Authors:  Anna Maria Calcagno; Crystal D Salcido; Jean-Pierre Gillet; Chung-Pu Wu; Jennifer M Fostel; Melanie D Mumau; Michael M Gottesman; Lyuba Varticovski; Suresh V Ambudkar
Journal:  J Natl Cancer Inst       Date:  2010-10-08       Impact factor: 13.506

6.  Differential expression of steroid receptors, hsp27, and pS2 in a series of drug resistant human breast tumor cell lines derived following exposure to antitumor drugs or to fractionated X-irradiation.

Authors:  R D Whelan; B T Hill
Journal:  Breast Cancer Res Treat       Date:  1993       Impact factor: 4.872

7.  Tamoxifen stimulates in vivo growth of drug-resistant estrogen receptor-negative breast cancer.

Authors:  J Maenpaa; V Wiebe; S Koester; G Wurz; V Emshoff; R Seymour; P Sipila; M DeGregorio
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

8.  P-glycoprotein immunostaining correlates with ER and with high Ki67 expression but fails to predict anthracycline resistance in patients with advanced breast cancer.

Authors:  L Seymour; W R Bezwoda; R D Dansey
Journal:  Breast Cancer Res Treat       Date:  1995       Impact factor: 4.872

9.  P-Glycoprotein is not present in mitochondrial membranes.

Authors:  Jill K Paterson; Michael M Gottesman
Journal:  Exp Cell Res       Date:  2007-04-24       Impact factor: 3.905

10.  PSMB7 is associated with anthracycline resistance and is a prognostic biomarker in breast cancer.

Authors:  G Munkácsy; R Abdul-Ghani; Z Mihály; B Tegze; O Tchernitsa; P Surowiak; R Schäfer; B Györffy
Journal:  Br J Cancer       Date:  2009-12-15       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.